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Abstract
Background: Insulin resistance is the major pathogenesis underlying type 2 diabetes mellitus (T2DM) and these
patients have doubled risk of Alzheimer’s disease (AD). Increasing evidence suggests that insulin resistance plays an
important role in AD pathogenesis, possibly due to abnormal GSK3β activation, causing intra- and extracellular
amyloid-beta (Aβ) accumulation. Adiponectin (APN) is an adipokine with insulin-sensitizing and anti-inflammatory
effects. Reduced circulatory APN level is associated with insulin resistance and T2DM. The role of APN in AD has not
been elucidated. In this study, we aim to examine if adiponectin deficiency would lead to cerebral insulin resistance,
cognitive decline and Alzheimer’s-like pathology in mice.
Methods: To study the role of adiponectin in cognitive functions, we employed adiponectin-knockout (APN-KO) mice
and demonstrated chronic APN deficiency in their CNS. Behavioral tests were performed to study the cognitions of male
APN-KO mice. Brains and tissue lysates were collected to study the pathophysiological and molecular changes in the
brain of APN-KO mice. SH-SY5Y neuroblastoma cell line was used to study the molecular mechanism upon APN and
insulin treatment.
Results: Aged APN-deficient mice displayed spatial memory and learning impairments, fear-conditioned memory deficit
as well as anxiety. These mice also developed AD pathologies including increased cerebral Aβ42 level, Aβ
deposition, hyperphosphorylated Tau proteins, microgliosis and astrogliosis with increased cerebral IL-1β and
TNFα levels that associated with increased neuronal apoptosis and reduced synaptic proteins levels, suggesting APN
deficiency may lead to neuronal and synaptic loss in the brain. AD pathologies-associated APN-KO mice displayed
attenuated AMPK phosphorylation and impaired insulin signaling including decreased Akt induction and increased
GSK3β activation in the hippocampus and frontal cortex. Aged APN-KO mice developed hippocampal insulin resistance
with reduced pAkt induction upon intracerebral insulin injection. Consistently, APN treatment in SH-SY5Y cells with insulin
resistance and overexpressing Aβ induce higher pAkt levels through AdipoR1 upon insulin treatment whereas the
induction was blocked by compound C, indicating APN can enhance neuronal insulin sensitivity through AMPK activation.
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Conclusion: Our results indicated that chronic APN deficiency inactivated AMPK causing insulin desensitization and
elicited AD-like pathogenesis in aged mice which also developed significant cognitive impairments and psychiatric
symptoms.
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Background
Alzheimer’s disease (AD) is the most common cause of
dementia in the elderlies. AD brain pathologies are char-
acterized by deposition of extracellular amyloid-β
(Aβ)-containing senile plaques, intracellular hyperpho-
sphorylated Tau-containing neurofibrillary tangles (NFT),
neuroinflammation, synaptic loss and neuronal death,
leading to cognitive impairments. Aging and apolipopro-
tein E ε4 allele are known risk factors. Recently, type 2
diabetes mellitus (T2DM) is recognized as another risk
factor of AD. Accumulating evidence demonstrated that
T2DM and AD share similar pathophysiologies such as
insulin resistance, disrupted glucose and lipid metabolism,
inflammation and oxidative stress [1–5].
Cerebral insulin resistance is increasingly recognized
as an important factor of AD pathogenesis. A series of
studies has shown a strong association between insulin
signaling and Aβ metabolism. Notably, Aβ oligomers,
including dimers, trimers and dodecamers (Aβ*56), are
the early neurotoxic species in AD. Cerebral insulin re-
sistance results in glycogen synthase kinase 3β (GSK3β)
activation, leading to increased Aβ production and Tau
phosphorylation [6–8]. It was reported that insulin
resistance increased extracellular Aβ deposition by
enhancing γ-secretase activity, which is involved in Aβ
production, thereby promoting Aβ secretion from neu-
rons [9]. In contrast, insulin inhibits the GSK3β activity
to prevent generation of Aβ and hyperphosphorylated
Tau [8, 10]. Studies using transgenic AD mice models
revealed that the transgenic mice exhibited hippocampal
insulin resistance [11]. Leptin-deficient mice, a T2DM
model, displayed impaired cerebral insulin signaling and
cognitive impairments after treating with high-fat-diet
[12, 13]. Postmortem study of AD brains indicated
significant increase of insulin receptor substrate-1 (IRS-
1) phosphorylation at serine residues, marker of insulin
resistance. In addition, insulin resistance is associated
with impaired synaptic plasticity [14]. Insulin administra-
tion reduced chronic neuroinflammation and microglia ac-
tivation as well as enhanced synapse formation in AD
mouse model [15, 16]. These studies established the associ-
ations between AD, cerebral insulin resistance and T2DM.
Adiponectin (APN) is an adipocyte-secreted circulat-
ing hormone, which exerts insulin sensitizing, anti-
inflammatory and anti-oxidative effects to peripheral
tissues. APN exists in three oligomeric forms in
circulation, including trimers, hexamers and high mo-
lecular weight (HMW) oligomers [17]. T2DM patients
and aged individuals have reduced circulating APN
levels [18]. APN deficiency is associated with peripheral
insulin resistance in mice and human, causing T2DM
and DM-related syndromes [19, 20], whereas whether
adiponectin is associated with cerebral insulin sensitivity
has not been documented. Studies indicated APN can
ameliorate insulin sensitivity by enhancing AMP-
activated protein kinase (AMPK) phosphorylation,
thereby, activating insulin receptor substrate (IRS) phos-
phorylation at Tyrosine residues. This promotes insulin
signaling activities including insulin-mediated cell
survival by inhibiting GSK3β and glucose uptake by en-
hancing translocation of GLUT4 transporter [21, 22].
The role of APN in the central nervous system (CNS) is
not well characterized. Adiponectin receptors (AdipoR1 &
AdipoR2) are abundantly expressed in the hippocampus,
cortex and hypothalamus [23, 24]. Only trimeric and
hexameric APN are detectable in human cerebrospinal
fluid (CSF) suggesting that low molecular weight APN can
cross the blood-brain barrier (BBB) and has a role in CNS
[25]. APN has shown to be important in neurogenesis and
proliferation of hippocampal neural stem cells [26, 27]. It
has also been reported that APN-deficient mice exhibited
depressive-like behavior [23]. Physical activities and envir-
onmental enrichment can increase cerebral APN levels
that exerted anti-depressive effects and reduced neuroin-
flammation in mice [27]. Loss of APN in mice also exacer-
bated the severity of encephalomyelitis by activating
lymphocytes in the mouse model of multiple sclerosis
[28]. Clinical reports revealed association between
decreased APN levels and ischemic stroke. APN treatment
in mice with cerebral ischemia improved neurobehavioral
performance and focal cerebral neurogenesis [29]. T2DM
patients with lower serum APN levels have a lower mean
hippocampal volume than T2DM patients with normal
adiponectin levels [30]. Our previous findings demon-
strated APN to be protective against Aβ neurotoxicity
[31]. Although a recent publication showed an association
between APN gene polymorphism and late onset AD [32],
there are contradictory clinical reports on the difference
of plasma APN level between non-demented control and
AD or mild cognitive impairment patients [33–35]. The
role of APN in AD remains uncertain. We, therefore,
investigated if chronic APN deficiency would result in
Ng et al. Molecular Neurodegeneration  (2016) 11:71 Page 2 of 16
cerebral insulin resistance which is associated with AD-
like pathologies, and cognitive impairments in aging mice.
In this study, we employed adiponectin knockout
(APN-KO) mice to mimic the condition of chronic APN
deficiency in T2DM patients and aged subjects, and
demonstrated that there were cerebral insulin resistance
and deregulated insulin signaling upon APN deficiency.
The mice also exhibited memory decline and anxiety
associated with AD pathologies including increased Aβ
production, Tau phosphorylation, neuroinflammation
and neurodegeneration. Our study provides novel
evidence on the role of adiponectin in cerebral insulin
sensitivity, development of AD-like pathologies and cog-
nitive impairment.
Results
Chronic APN deficiency in CNS of APN-KO Mice
Trimeric APN could cross the BBB [27]. Recent studies
showed that mRNA of adiponectin receptors were
expressed in mouse brain. We performed immunofluor-
escent staining of AdipoR1 confirming that AdipoR1
protein is expressed in the cortex and hippocampus of
mouse (Additional file 1). This indicated that the brain
can respond to adiponectin present in the CNS. To
verify if endogenous APN is present in WT mice and ab-
sent in APN-KO mice, the concentration of APN in CSF
was determined by semi-quantitative dot-blot immuno-
assay. With reference to the standard curve (Additional
file 1), concentrations of APN in CSF of 18-mth old WT
mice were 428 ng/mL ± 156 ng/mL (n = 4, p < 0.05),
whereas APN was undetectable in the CSF of aged
APN-KO mice (Additional file 1). The APN-KO mice
had chronic deficiency of APN, not only in peripheral
tissues, but also in the CNS.
Aged APN-KO mice had anxiety, and impaired spatial
learning and memory loss
To evaluate if psychiatric symptoms may be related to
APN deficiency in aged individuals, we performed open
field test to investigate the anxiety level in APN-KO
mice. Both 9-mth-old & 18-mth-old APN-KO spent sig-
nificantly longer time in the margin area and shorter
time in the center area (14.05% ± 2.28% in 9-mth-old
WT mice vs 7.34% ± 2.19% in 9-mth-old APN-KO mice,
Fig. 1a; 15.99% ± 1.43% in 18-mth-old WT mice vs
10.32% ± 1.41% in 18-mth-old APN-KO mice, mean ±
S.E.M, p < 0.05, Fig. 1b), indicating that chronic APN defi-
ciency in mice was associated with increased anxiety level.
To assess the spatial learning and memory abilities of
aging APN-KO mice, we employed a hidden platform
version of the Morris-Water-Maze. Time required to
locate the hidden platform during acquisition phase was
analyzed. In the test, mice were trained with visible plat-
form so that they could learn to locate the platform. The
visible platform tests showed that both WT and APN-
KO mice had a similar trend of escape latency in all 4
sessions (p > 0.05) by 9-mths-of-age and 18-mths-of-age,
suggesting that aging did not significantly affect the
locomotor activity and vision in WT and APN-KO mice.
9-mth old APN-KO adult mice showed no significant
spatial learning and memory impairment (p > 0.05,
Fig. 1c). However, we observed moderate prolongation
in the latency of locating the hidden platform in
18-mth-old APN-KO mice. Although WT and APN-KO
mice have had similar escape latency in the first two ses-
sions, there were significant differences in the third and
fourth sessions, suggesting that aged APN deficient mice
had spatial memory and learning impairment (p < 0.05,
Fig. 1d), which was not due to differences in swim speed,
visual acuity or locomotor deficits as demonstrated by
visible platform test and swim speed recording (Add-
itional file 2). In addition, the probe tests indicated that
9-mth old APN-KO mice spent comparable time in the
target quadrant (compared with WT, p > 0.05; Fig. 1e).
In contrast, 18-mth-old APN-KO mice spent signifi-
cantly less time in the target quadrant, suggesting there
is a reference memory retention deficit in aged APN-KO
mice (p < 0.05, Fig. 1f ). These results revealed that
chronic APN deficiency in aged mice was associated
with spatial learning and memory impairments.
Hence, the APN-KO mice had increased anxiety level.
To further confirm that aged APN-KO mice suffered
from learning and memory deficits, we performed con-
textual and cue fear-conditioning test, a stress-associated
memory task, governed by hippocampus, amygdala and
is cortical-associated. 12-mth old WT mice displayed
robust contextual fear conditioning 1 day later with
freezing 68.58% ± 6.65%. In contrast, 12-mth old
APN-KO mice froze significantly less (14.68% ± 3.08%;
p < 0.001 versus WT mice; Additional file 3). When
the mice were placed in a novel environment and ex-
perienced with the same cue without shock, APN-KO
mice also froze less than the WT mice (51.71% ±
4.99% in WT mice vs 30.29% ± 3.93% in APN-KO
mice; p < 0.05, Fig. 1g & Additional file 4). These
results provided further support that chronic APN
deficiency was associated with impaired hippocampus-
dependent learning and memory upon aging.
Aged APN-KO mice had AD-like brain pathologies
To investigate if chronic APN deficiency could lead to
increased Aβ production and Aβ oligomers, sections
from 18-mth old wildtype and APN-KO mice were
stained with antibody (clone 4G8) against Aβ. Faint Aβ-
immunoreactive deposits were found in the cortex of
APN-KO mice by 18 months but no plaque was present
in the wildtype mice. ThioFlavin S staining also indicated
the presence of Aβ deposits in APN-KO mice by
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18 months-of-age (Fig. 2a). Levels of Aβ1-42 in WT and
APN-KO mice were also determined by Sandwich
ELISA. Aβ1-42 levels in the hippocampus of 9-mth
old APN-KO mice were comparable with that of WT
mice (WT, 20.12 ± 2.16 pg/mg of protein vs APN-KO,
21.06 ± 8.96 pg/mg of protein; p > 0.05) (Fig. 2a).
Moreover, soluble Aβ1-42 levels in the frontal cortex
of 9-mth-old APN-KO mice were insignificantly
higher than that of the WT mice (WT, 16.37 ± 2.29 pg/mg
of protein vs APN-KO, 19.06 ± 2.08 pg/mg of protein;
p > 0.05) (Fig. 2b). However, Aβ1-42 levels were sig-
nificantly increased in both the hippocampus (WT,
13.45 ± 2.87 pg/mg of protein vs APN-KO, 46.77 ±
11.58 pg/mg of protein; p < 0.05) and frontal cortex
(WT, 16.15 ± 3.52 pg/mg of protein vs APN-KO,
58.41 ± 16.67 pg/mg of protein; p < 0.05) of APN-KO
mice relative to the wildtype mice by 18 month
(Fig. 2b). In addition, we performed western blot by
using 4G8 antibody to further verify the presence of
Aβ oligomers in APN-KO mice. Interestingly, a
distinct 56 kDa band was detected in the hippocam-
pal and frontal cortical lysate of APN-KO mice by
18-month (Fig. 2c) but not by 9-month old. Aβ*56 is
specific oligomeric species present in early AD mice
and aged human subjects [36, 37]. These results sug-
gested that chronic APN deficiency in aged mice led
to increased cerebral Aβ accumulation.
To study whether Tau protein phosphorylation was in-
creased in APN-KO mice, we evaluated the levels of
pTauS199/S202 & pTauS396 in hippocampus and frontal cortex
by western blot. Though Tau5 (total tau) expression varied
between the WT and APN-KO mice, results revealed that
18-month old APN-KO mice had increased Tau phosphor-
ylation at both serine199/202 and serine396 in hippocampus
and frontal cortex relative to that of wildtype mice (Fig. 2d).
AD-like neuroinflammation, increased neuronal apoptosis
and reduction of synaptic proteins in aged APN-KO mice
To determine if neuroinflammation was present in the
brain of aged APN-KO mice, we initially examined
a
Center %
Wild-type APN-KO 
0
5
10
15
20
D
ur
at
io
n 
%
*
18-month-old9-month-old
Margin %
Wild-type APN-KO 
0
20
40
60
80
100
D
ur
at
io
n 
%
*
Margin %
Wild-type APN-KO 
0
20
40
60
80
100
D
ur
at
io
n 
%
*
Center %
Wild-type APN-KO 
0
5
10
15
20
D
ur
at
io
n 
%
*
(Open field Test) (Open field Test)
b dc 9-month-old 18-month-old
1 2 3 4
0
10
20
30
40
50
Session
E
sc
ap
e 
La
te
nc
y 
(S
ec
on
d)
Visible Platform (Latency)
Wild-type 
APN-KO
1 2 3 4
0
10
20
30
40
50
Session
E
sc
ap
e 
La
te
nc
y 
(s
ec
on
ds
)
Visible platform (Latency) 
Wild-type 
APN-KO
Hidden platform  (Latency)
1 2 3 4 5 6
0
10
20
30
40
Session
E
sc
ap
e 
La
te
nc
y 
(s
ec
on
ds
) Wild-type
APN-KO**
** (n= 9)
(n= 8)
(n= 9)
(n= 8)
1 2 3 4
0
10
20
30
Session
E
sc
ap
e 
La
te
nc
y 
(s
ec
on
ds
)
Hidden platform  (Latency)
Wild-type 
APN-KO
(n= 11)
(n= 11)
(n= 11)
(n= 11)
(Morris Water Maze) (Morris Water Maze)
Day5 Day7 Day9
0
10
20
30
40
50
%
 o
f t
im
e 
sp
en
t i
n 
ea
ch
 q
ua
dr
an
t
Probe Test
Wild-type 
APN-KOn.s n.s
*
Day5 Day7 Day9
0
20
40
60
80
%
 o
f t
im
e 
sp
en
t i
n 
ea
ch
 q
ua
dr
an
t
Probe Test
Wild-type 
APN-KO*
*
(n= 11)
(n= 11)
(Target Quadrant) (Target Quadrant)
Pre-shock Pre-Cue Contextual Cue
0
20
40
60
80
100
Fr
ee
zi
ng
 %
Fear Conditioning Test
Wild-type 
APN-KO
***
*
(n=4)
(n=5)
(n= 9)
(n= 8)
g 12-month-old9-month-old 18-month-oldfe
Fig. 1 Cognitive impairments of aged APN-KO mice in behavioral tests. In open-field test, time spent in marginal area and center area for both
(a) 9-mth-old & (b) 18-mth-old wildtype and APN-KO mice were assessed. c 9-mth-old & (d) 18-mth-old APN-KO mice were trained with visible platform
for 16 trials (4 trials/day) and hidden platform for 6 days (4 trials/day) to learn and search in the Morris-Water-Maze tests. Probe tests were performed for
both (e) 9 mth & (f) 18-mth old mice, in which platform had been removed to investigate the time spent in platform quadrant. (g) Freezing times of the
12-mth-old mice were recorded in both contextual and cue test, indicating the APN-KO mice exhibited memory impairments. *p< 0.05, **p< 0.01, ***p< 0.001
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changes of expression of Iba-1, a marker of microglia, in
the cortex. Consistent with the robust inflammation
reported in AD brains and AD mice model, higher num-
ber of Iba1-positive cells was observed in APN-KO by
18-mth (Fig. 3a). Astrogliosis is another pathological
hallmark of AD, we then performed immunohistochem-
istry staining of GFAP in the brain sections of aged
APN-KO mice. The number of GFAP-immunoreactive
astrocytes in the CA1 regions of the hippocampus was
significantly increased and astrocytes displayed
hypertrophic changes. Quantitative analysis was also
performed to confirm an increase in the number of
Iba-1-positive cells in APN-KO mice, as compared with
the wildtype mice. Furthermore, quantitative analysis
revealed that the percentage of the area occupied by
GFAP-positive cells was increased in the hippocampus
of the APN-KO mice compared with the wildtype mice
(Fig. 3b). We subsequently studied the expression of
MHCII, a marker of proinflammatory activation (M1) of
microglia, by western blot. The substantial increase of
MHCII expression in both frontal cortex and hippocampus
of 18-month old APN-KO mice indicated that the
mice had reactivation of microglia and chronic cere-
bral inflammation (Fig. 3c). Reactivated microglia se-
crete proinflammatory cytokines (e.g., TNFα & IL-1β)
that can cause synaptic loss [38, 39]. We then examined
the cerebral levels of TNFα and IL-1β in APN-KO mice
by ELISA assay. Both IL-1β and TNFα levels were
increased in the aged APN-KO mice compared with
wild-type mice of the same age (Fig. 3d). Together,
these data suggested that APN deficiency led to
neuroinflammation in aged mice.
To explore whether the cognitive impairments in aged
APN-KO mice were associated with neurodegeneration,
we evaluated neuronal apoptosis by double immuno-
fluorescent staining of NeuN and TUNEL. Neuronal
apoptotic cells in the hippocampus CA1 and cortex were
markedly increased in aged APN-KO mice compared
with wildtype mice (Fig. 4a). Quantitative analysis
revealed that the estimated number of apoptotic cells in
cortical defined regions in APN-KO was significantly
higher than that of the wildtype mice (214.0 ± 26.2 vs
Fig. 2 Increase of Aβ production and Tau phosphorylation in aged APN-KO mice. a Immunohistochemistry analysis of anti-Aβ (4G8) showed accu-
mulation of Aβ (Brown) in the cortex of 18-month APN-KO mice. b ELISA analysis of soluble Aβ1–42 in the hippocampal and frontal cortical lysate
of 9-month and 18-month old mice. c Immunoblotting of mouse Aβ by antibody 4G8 showing the presence of Aβ*56 in the hippocampus and
frontal cortex of 18-mth old APN-KO mice. d Immunoblotting of pTau serine199 & 202, pTau serine396 and Tau5 (total tau) in the hippocampus and
frontal cortex of 18-mth old mice. Mean ± S.E.M.; *p < 0.05, **p < 0.01, n.s. statistically not significant; WT (n = 4) vs APN-KO (n = 6). Scale bar: 50 μm
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46.3 ± 11.9; p < 0.05). In addition, the number of apop-
totic cells in hippocampal CA1 region was also
dramatically higher in APN-KO mice (44.0 ± 7.6 vs 11.3
± 3.5; p < 0.01) than in wildtype mice, indicating that the
number of apoptotic neurons was increased in APN-KO
mice (Fig. 4b). To study whether the presence of Aβ
oligomers and increased proinflammatory cytokines in
the APN-KO mice were associated with synaptic loss,
we examined the levels of spinophilin (post-synaptic
protein) and synaptophysin (pre-synaptic protein) which
are the common synaptic markers used to determine
synaptic density. Western blot analysis showed that the
level of synaptophysin was reduced significantly in the
hippocampus and frontal cortex whereas spinophilin
was reduced in the hippocampus of the aged APN-KO
mice (Fig. 4c & d). Altogether these results suggested
that chronic APN deficiency in CNS was associated with
neuroinflammation and possibly led to neuronal apop-
tosis and synaptic loss. They provided an explanation for
the cognitive impairments observed in the aged APN-
KO mice.
Chronic APN deficiency led to attenuated AMPK
activation causing deregulated insulin signaling pathways
and cerebral insulin resistance
In peripheral tissues, APN signaling leads to AMPK
activation, which reduces IRS-1 phosphorylation at
serine residues to enhance insulin sensitivity [22, 40, 41].
To assess if there are changes of cerebral AMPK
activities and insulin signaling between aged WT and
APN-KO mice, we performed Western blot analysis to
study the protein levels of main effectors in AMPK and
insulin signaling. We found that there was drastic de-
crease of AMPK phosphorylation at threonine 172
(pAMPKT172) in the frontal cortex and hippocampus of
younger APN-KO mice (9-mth-old; Fig. 5a). Though
AMPK phosphorylation was reduced insignificantly in
the frontal cortex of APN-KO mice by 18-month-of-age,
pAMPKT172 in the hippocampus was reduced signifi-
cantly in APN-KO compared to aged WT mice (Fig. 5b).
Concomitantly, pIRS-1S616 level was increased in the
frontal cortex of aged APN-KO mice (18-mth-old;
Fig. 5c), indicating that chronic APN deficiency might
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Fig. 3 Microglial reactivation and increased cerebral proinflammatory cytokines in APN-KO mice. a Representative image of immunohistochemistry
staining of Iba-1 and GFAP represents the present of activated microglia (Brown, black arrows) and astrocytes respectively in the cortex of 18-mth old
wildtype and APN-KO mice. b The percentage of Iba1 and GFAP positive stained area in the cortex of mice. c MHCII, M1 microglial activation marker,
was detected in the frontal cortex and the hippocampus of APN-KO mice. d Cerebral IL-1β and TNFα levels detected by ELISA indicated significant increase
in the 18-mth-old APN-KO mice. Mean± S.E.M.; *p< 0.05, **p< 0.01, ***p< 0.001, n.s. statistically not significant; WT (n=3) vs APN-KO (n=3 or 4). Scale bar: 50 μm
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lead to neuronal insulin resistance through inhibition of
the AMPK-IRS1 signaling cascade.
pIRS-1S616 hinders the formation of activated form
pIRS-1Tyr, inactivating insulin signaling [6]. To examine
whether chronic APN deficiency deregulated insulin
signaling in neurons of aging mice, we performed west-
ern blotting to determine the level of phosphorylated
Akt, GSK3α/β and Erk1/2. The levels of pAktS473,
pGSK3αS21 (inhibitory form of GSK3α) and pGSK3βS9
(inhibitory form of GSK3β) were decreased while
pGSK3βY216 levels were drastically elevated in the frontal
cortex and hippocampus of 9-mth-old APN-KO mice
(Fig. 5d). We also found that level of pErk1/2 was
reduced in both the frontal cortex and hippocampus of
9-mth old APN-KO mice, further indicating the disrup-
tion of insulin signaling (Additional file 5). In addition,
there was no significant change in the level of insulin
receptor (IR) suggesting that the reduced insulin signal-
ing activities was not associated with reduced IR level
(Additional file 6). Interestingly, the levels of IR, pAkt
S473, pGSK3αS21, pGSK3βS9 and pErk1/2 were increased
significantly in the hippocampus of 18-mth-old APN-
KO mice but reduced in the frontal cortex compared to
WT mice. pGSK3αY279/βY216 levels reduced insignifi-
cantly in the hippocampus between WT and APN-KO
mice by 18-month old. However, the level of
pGSK3βY216 was higher in the frontal cortex of APN-KO
mice (Fig. 5e, Additional file 5).
Since the endogenous plasma insulin level in APN-KO
mice was comparable with the WT mice [42], the im-
paired insulin signaling activities may be due to changes
in neuronal insulin sensitivity. To assess if there was
changes in neuronal insulin sensitivity in aged APN-KO
mice, we injected insulin (2 IU/kg body weight) to the
right hippocampus of 12-mth-old APN-KO mice using a
stereotaxic injection approach. We confirmed the position
of injection by injecting a visible dye (Additional file 7).
We found that induction of Akt activation after insulin
injection to the right hippocampus was significantly re-
duced in the aged APN-KO mice compared to WT mice
(Fig. 5f). The hippocampus of aged APN-KO mice was
less sensitive to insulin compared to that of WT mice.
Fig. 4 Neuronal apoptosis and synaptic proteins reduction in 18-month old APN-KO mice. a Representative images show TUNEL-labeled (Red)
apoptotic cells countered stained with DAPI (blue) in the cortex and hippocampus between 18-month old wildtype and APN-KO mice. b Graph
demonstrates the differences of quantified numbers of TUNEL-labeled cells in the cortex and hippocampal CA1 region in wildtype and APN-KO
mice. Two sampling regions (Blue square) in the cortex and one sampling region (red) in the hippocampal CA1 were defined. c Immunoblotting
of synaptic proteins, synaptophysin and spinophilin in the hippocampus and frontal cortex of 18-mth old wildtype and APN-KO mice. d Densitometric
analysis of synaptophysin and spinophilin demonstrating the differences of these synaptic proteins in the frontal cortex and hippocampus between wildtype
and APN-KO mice. Mean ± S.E.M.; *p < 0.05, **p < 0.01, ***p < 0.001, n.s. statistically not significant; WT (n= 4) vs APN-KO (n= 4) Scale bar: 50 μm
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This indicated that chronic APN deficiency led to cerebral
insulin resistance. Our results demonstrated that chronic
APN deficiency was associated with cerebral insulin resist-
ance and provided a possible molecular mechanism for
the pathogenesis of AD in aged APN-KO mice.
APN ameliorates neuronal insulin sensitivity through
AdipoR1-mediated AMPK activation
To study the insulin sensitization effect of APN in neur-
onal culture, human neuroblastoma SH-SY5Y cell line
was induced with insulin resistance (SH-SY5YIR) by high
concentration insulin. The pAkt level of SH-SY5YIR cells
did not increase after culturing with low concentration
insulin (10 nmol/L) showing the presence of insulin
resistance (p > 0.05). Mammalian trimeric APN restored
the induction of pAkt and pGSK3βS9 levels in the
SH-SY5YIR cells with increased AMPK phosphorylation
when cultured with 10 nmol/L insulin, demonstrating
that APN could ameliorate neuronal insulin resistance.
Furthermore, Compound C (2 μM), an AMPK inhibitor,
blocked the insulin sensitizing effect of adiponectin as
pAkt and pGSK3βS9 levels were reduced in the
SH-SY5YIR cells (Additional file 8). This indicated that
APN enhanced neuronal insulin sensitivity to inhibit
GSK3β activity by activating AMPK signaling.
We further examined which adiponectin receptor was
involved in APN-enhanced insulin sensitivity in Aβ-pro-
ducing neurons and whether APN can reduce Aβ pro-
duction from neuronal cells. SH-SY5Y cells stably
transfected with Swedish mutation of APP (SH-SY5YswAPP)
produced Aβ oligomers, mimicking the AD neurons, as we
reported previously [31]. SH-SY5YswAPP transfected with a
Fig. 5 APN deficiency attenuated AMPK phosphorylation causing insulin resistance and deregulated insulin signaling in APN-KO mice. Representative
image of immunoblotting indicated reduction of pAMPKT172/AMPK ratio in both the hippocampus and frontal cortex by (a) 9-mth-old
and (b) 18-mth-old of APN-KO mice. c Increased level of IRS-1 phosphorylation at Serine 616 shown by immunoblotting in the frontal
cortex of APN-KO mice. Representative immunoblotting analysis and densitometric analysis of the ratio of insulin signaling effectors (pAktS473/Akt,
pGSK3βS9/GSK3β, pGSK3βY216/GSK3β) in the hippocampus and frontal cortex of APN-KO mice or WT mice by (d) 9-mth-old & (e) 18-mth-old WT and
APN-KO mice. f Representative image and densitometric analysis of pAkt level induction in the right hippocampus of WT mice and APN-KO mice in
response to stereotaxic insulin injection. Mean ± S.E.M.; *p < 0.05, **p < 0.01, ***p < 0.001, n.s. statistically not significant; WT (n = 3) vs APN-KO (n = 3 or 4)
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combination of siAdipoR1 and siAdipoR2 had reduced
expression of AdipoR1 and AdipoR2 respectively (Fig. 6a).
AMPK phosphorylation was blocked in both cells trans-
fected with AdipoR1 and AdipoR2 RNAi duplex upon
APN treatment (Fig. 6b). Addition of insulin induced pAkt
and pGSK3βS9 levels while addition of mammalian trimeric
APN (10 μg/mL) further enhanced higher levels of pAkt
and pGSK3βS9 in SH-SY5YswAPP cells when cultured with
10 nmol/L insulin. This implicated that APN could also
enhance insulin sensitivity in Aβ-overproducing neuroblast-
oma cells. However, the pAkt and pGSK3βS9 levels were
not increased in AdipoR1-RNAi-transfected SH-SY5YswAPP
when cultured with APN and insulin compared to the cells
cultured with insulin only. In contrast, pAkt and pGSK3βS9
levels were further enhanced upon APN plus insulin treat-
ment in SH-SY5YswAPP cells transfected with AdipoR2
RNAi (Fig. 6c). APN reduced extracellular Aβ levels
whereas the reduction was abrogated when SH-SY5YswAPP
cells were transfected with AdipoR1-RNAi. Interestingly,
extracellular Aβ levels were also reduced though
nonsignificant in AdipoR2-RNAi-transfected cells upon
APN treatment (Fig. 6d). These data suggested APN was
effective in neuronal insulin-sensitization through
AdipoR1-AMPK activation and could be a possible thera-
peutic agent in AD.
Discussion
Our study demonstrated that aged mice with chronic
APN deficiency in brain had spatial memory and fear-con-
ditioned memory impairments as well as anxiety. Cogni-
tive impairments in these aged mice were associated with
AD-like pathologies including increased Aβ oligomers and
hyperphosphorylated Tau. In addition, neuroinflammation
was also found in aged APN-KO mice, as evidenced by
substantial microglial reactivation together with elevated
proinflammatory cytokines (TNFα and IL-1β levels. In-
creased apoptosis and reduction of hippocampal synaptic
proteins suggested neuronal and synaptic loss in the aged
APN-KO mice, which could be related to neurotoxic Aβ
oligomers accumulation and elevated proinflammatory
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Fig. 6 APN enhanced neuronal insulin sensitivity in vitro. a AdipoR1 and AdipoR2 expressions in SH-SY5YswAPP cells upon RNAi transfection.
b Representative image of pAMPK levels upon APN treatment in SH-SY5YswAPP cells transfected with scrambled, AdipoR1 or AdipoR2 RNAi duplex.
c Representative images of western blot of pAkt, Akt, pGSK3βS9 and GSK3β in SH-SY5YswAPP cells transfected with scrambled, AdipoR1 or AdipoR2
RNAi duplex that cultured with/without 10 nmol/L insulin, APN or with 10 μg/mL trimeric APN (APNTri) & 10 nmol/L insulin. d Levels of extracellular
Aβ42 upon APN treatment in SH-SY5YswAPP cells transfected with scrambled, AdipoR1 or AdipoR2 RNAi duplex. Mean ± S.E.M.; *p < 0.05, **p < 0.01,
***p < 0.001, n.s. statistically not significant
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cytokines levels. Importantly, cerebral insulin resistance
developed in the aged APN-KO mice with attenuated
AMPK activation and impaired insulin signaling which
was an underlying mechanism of AD pathogenesis. Con-
comitantly, our in vitro experiments showed that APN
ameliorated neuronal insulin resistance. APN enhanced
insulin sensitivity and reduced Aβ production through
AdipoR1-mediated AMPK activation. The role of APN in
molecular signal of AD pathogenesis was proposed based
on findings of the present study (Fig. 7). All these sup-
ported the cognitive impairments in APN-deficient mice
were associated with cerebral insulin resistance, AD-like
brain pathologies and mimicked the phenotypes of AD pa-
tients and rodent models.
Accumulating evidence suggests that insulin resistance
and inflammation are involved in the pathogenesis of both
T2DM and AD [6, 39, 43]. Leptin, an adipokine has simi-
lar actions as APN in enhancing insulin sensitivity of
peripheral tissues, has also been reported with neuropro-
tective effects. Leptin receptor-deficient mice, a T2DM
model, had an age-dependent cognitive decline with
reduced synaptic density and increased tau phosphoryl-
ation [13]. Despite that APN deficiency has a strong
association with T2DM, the role of APN in AD is contro-
versial. Considering the insulin sensitizing and anti-
inflammatory effects of APN in peripheral tissues, APN
may exert neuroprotective effects against AD pathogen-
esis. However, elevated plasma APN levels in AD patients
were reported in some populations or specific gender
[33, 44]. Meanwhile, another clinical study demon-
strated that decreased serum APN level is associated
with mild cognitive impairments and AD [34]. A
recent publication reported that polymorphisms in
the APN gene locus were associated with higher risk
of AD [32]. Although it is believed that APN crosses
the BBB from the systemic circulation to the CNS,
the changes of circulatory APN level may not reflect
the changes of APN level in the CNS. Most import-
antly, there was no significant difference of CSF adi-
ponectin between normal subjects and AD patients,
indicating AD onset might not be associated with in-
creased level of CSF APN [35]. Moreover, the changes
in plasma APN level in AD could be either the cause
or consequence of AD onset. To assess the conse-
quence of the changes in protein level, a knockout
animal would be a better approach. Therefore, we
employed APN-KO mice as the model. The aged
mice were provided with chow diet, normal social
interaction, minimized stress environment as well as
prolonged APN deficiency to mimic the condition in
T2DM patients and elderly. We confirmed the ab-
sence of APN in CSF by dot-blot immunoassay. The
aged APN-KO mice had spatial memory impairments
and anxiety. Remarkably, the mice also displayed
AD-like pathologies including Aβ oligomers accumu-
lation, Tau hyperphosphorylation, neuroinflammation
and possibly synaptic loss. Our results suggested that
chronic APN deficiency in CNS led to cognitive impair-
ments. However, whether the elevated plasma APN levels
reported in AD patients [44] was a compensatory mech-
anism for AD onset requires further investigation.
Aβ is believed to be one of the major neurotoxic
species in AD pathogenesis. Our results have shown that
soluble Aβ peptide production was increased along with
the present of Aβ*56 (dodecamers) in APN-KO mice by
18-month. Unfortunately, low-molecular mass of mouse
Aβ was hard to be detected by western blotting. We are
the first group to show that Aβ*56 can be detected in
mice without APP transgene. Aβ*56 is a specific oligo-
meric Aβ species present at higher levels in aging indi-
viduals with normal cognition and patients with mild
cognitive impairments than patients with AD. This Aβ
oligomeric species is positively correlated with Tau CP13
(pTauS202) level and negatively correlated with synaptic
proteins in AD patients [36]. Injection of Aβ*56 into
healthy rat induced memory impairments suggesting this
specific Aβ oligomer species might initiate age-
associated memory impairments, and possibly the action
was independent of neuronal loss but related to changes
in synaptic functions [37]. It is observed that adiponectin
level decreases in aging, hence delineating the molecular
linkage between adiponectin and Aβ*56 formation may
elucidate the mechanism of aged-related memory
decline and even the onset of AD.
Our results clearly suggest that APN has an important
role in cognitive functions of mammals. The mecha-
nisms underlying APN activity in the CNS are poorly
understood. It has been shown that APN receptors are
abundantly expressed in the mammalian brain and APN
can enhance hippocampal neural stem cells by inducing
p38MAPK and inhibiting GSK3β activities [26]. These
two molecules are important intracellular mediators of
insulin signaling. Substantial evidence demonstrated that
GSK3α/β activation led to AD pathologies including Aβ
oligomerization, Tau hyperphosphorylation and synaptic
loss [8, 10, 45]. It is well characterized that APN stimu-
lates the activation of AMPK in peripheral tissues to
enhance phosphorylation of IRS-1 at tyrosine residues
that increase pAktS473 levels. pAktS473 can promote
insulin-mediated inhibition of GSK3β. Postmortem
studies revealed the increase of pIRS-1S616 and activated
GSK3β in AD brains [1]. Here, we propose that APN-
AdipoR1-AMPK-induced insulin signaling activities may
be important to protect aging brain from AD pathogen-
esis through GSK3β inhibition. These imply that APN is
essential in enhancing cerebral insulin signaling to main-
tain normal cognitive functions. Future studies may be
required to investigate if APN can regulate cerebral
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glucose metabolism through p38MAPK activation or
other insulin signaling responses.
We found that the insulin sensitivity was reduced by
9 months in the hippocampus and frontal cortex but
were enhanced by 18 months in the hippocampus of
APN-KO mice. It is possible that some unknown com-
pensatory mechanisms might have been activated in the
hippocampal neurons. One of the possible mechanisms
is the overexpression of insulin receptor (IR) in the
hippocampus, but not in the frontal cortex, to enhance
insulin signaling as observed in 18-mth-old APN-KO
mice (Additional file 2: Figure S2a & b). Overexpression
of IR in the hippocampus may therefore induce Akt
phosphorylation and inhibit GSK3. In addition to the
Akt/GSK3 pathway, pErk1/2 was also increased solely in
the hippocampus of 18-mth-old APN-KO mice. How-
ever, the improved insulin signaling could not reverse
loss of synaptic proteins in aged APN-KO mice.
Therefore, we observed cognitive impairments in the
18-mth-old APN-KO mice.
Inflammation is not only crucial in body defense
mechanism but is also playing critical roles in neurode-
generation and T2DM. TNFα levels are increased in
subjects with obesity and T2DM. Several studies have
demonstrated the presence of proinflammatory cyto-
kines and reactivated microglia in AD brains [46–48]. In
this study, we showed that the number of activated
microglia was increased in APN-KO mice and both cere-
bral IL-1β and TNFα levels were increased. Surveillance
microglia is responsible to recognize and remove extra-
cellular Aβ oligomers. Aβ oligomers in the cortex and
hippocampus of APN-KO mice may induce microglial
activation, leading to secretion of the proinflammatory
cytokines. We believe that APN might directly regulate
the activation state of microglia. Though there is still no
information on whether APN can regulate microglia
Normal State APN deficient State
Ramified
surveillance
microglia
Fig. 7 Schematic presentation shows the Adiponectin signaling pathway in neuron under normal (left) and disease (right) conditions. We proposed
that APN deficiency leads to decreased AMPK activation in neurons and increased IRS-1 phosphorylation at serine616 which inhibits the formation of
pIRS-1Tyr. Cerebral insulin resistance is progressively developed and thereby causing the reduced level of pAktS473. The GSK3α/β become activated and
may promote formation of Aβ oligomers and Tau phosphorylation. The accumulation of extracellular Aβ oligomers may induce M1 microglial reactivation
and secretion of proinflammatory cytokines that associated with neuronal apoptosis and synaptic loss, and subsequently cognitive decline in aged APN-KO mice
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activation, a recent report has demonstrated that micro-
glia expressed adiponectin receptors. Osmotin, plant
homolog of adiponectin, inhibited Toll-like receptor 4
(TLR4) in microglia cell line BV2 through AdipoR1 to
prevent LPS-induced inflammation [49]. Moreover,
astrocytes and macrophages also possess APN receptors
and being stimulated by APN, suggesting that APN can
regulate both cerebral and peripheral inflammation
[50, 51]. In addition to the increase of microglia-secreted
cytokines, TNFα can also be secreted from adipocytes
under APN deficient state or in APN-KO mice [42]. In
contrast, increased APN production can suppress TNFα
secretion from adipocytes [52]. Obese individuals and
T2DM patients have increased TNFα levels in their circu-
lation [53]. Plasma TNFα can cross the BBB and lead to
cerebral insulin resistance by inhibiting IRS-1 phosphoryl-
ation at tyrosine residues [1, 6, 11]. Hence, peripheral
inflammation due to chronic adiponectin deficiency may
also contribute to AD pathologies.
Conclusion
In summary, the current study demonstrated that
chronic APN deficiency might lead to cognitive decline
and AD-like pathologies through insulin desensitization.
It also raised the possibility that reduced CNS APN
levels in T2DM and aging subjects could indeed be one
of the causative factors of AD and cognitive impairment
due to deregulated cerebral insulin signaling or cerebral
insulin resistance. To our knowledge this is the first
study to shed light on the role and molecular mechan-
ism of APN on cognitive functions in mammals. This
supports the use of adiponectin or adiponectin receptor
agonists as target therapeutic agent in AD.
Methods
Animal
All mice were housed in a group of four to five per cage
and maintained in the Laboratory Animal Unit of the
University of Hong Kong. Mice were kept under 12 h-lights
on/12 h-dark cycle provided with free access food and
water. Heterozygous adiponectin mutants on C57BL/6 N
genetic background [54] were intercrossed to generate
APN-KO mice and wildtype littermate controls. Tail DNA
was collected for genotyping by PCR amplification. Detail
primer sequences and PCR conditions were used as
described previously [54]. All experiments were performed
with male mice only. All procedures were approved by the
Committee on the Use of Live Animals in Teaching and
Research of the University of Hong Kong.
Behavioral tests
Morris-Water-Maze test
All mice that subjected to behavioral studies were male.
APN-KO and WT mice of two age groups (9-months
and 18 months) were assessed for spatial reference
memory in the Morris Water Maze as described previ-
ously [55]. Mice were subjected to visible platform train-
ing for 2 consecutive days (4 trials per day) with
different platform location in each trial. Hidden platform
tasks were carried out in 6 consecutive days 24 h after
the last visible test trial. Memory retention was assessed
by three probe tests which were performed at the begin-
ning of the 5th, 7th and 9th day before the training was
started. The platform was removed and the time spent
in the target quadrant was recorded. Mice were allowed
to freely swim in 1 min and the distance traveled and
percent time spent in each quadrant were recorded
using a video tracking system (EthoVision 3.0, Noldus
Information Technology, Leesburg, VA, USA).
Open field test
APN-KO and WT mice of two age groups (9-months and
18 months) were put into a transparent plastic (26 × 26 ×
40 cm3) box and was allowed to freely explore the field in
a single 60-min session under dim light. The center area
was defined as 10 × 10 cm2 in the center of the open field.
Parameters including the velocity, time in movement, time
in the central/marginal zone, and average distance toward
the zone border or field center were recorded and ana-
lyzed by video tracking system (EthoVision 3.0, Noldus In-
formation Technology, Leesburg, VA, USA).
Fear condition test
The experimental procedures were followed as described
previously [56]. In brief, mice were placed individually
into a conditioning chamber (25 × 25 × 25 cm3) for
6 min of habituation in which the mice explored the
context freely. This was followed by 3 pairs of condi-
tioned stimulus (CS) (30 s, 4 Hz, 80 dB) and foot-shock
which was applied to the floor grid of the chamber as
the US (2 s, 0.5 mA). The inter-pair interval was 2 min
with 2 min rest after the final CS pair. The chambers
were cleaned with 70% alcohol between each training
session. For contextual and cued tests, mice were placed
at the same context for 8 min with no foot-shock and a
new context with explicit cue in the absence of foot-
shock respectively (Additional file 2). A video-tracking
system EthoVision XT7 (Noldus, Wageningen, The
Netherlands) was used for monitoring and recording
throughout the training and memory test sessions. The
videos were saved for later behavioral analysis.
Intracerebral injection
Mice were fasted overnight in cages and provided with
free access of water. Mice were anesthetized by ketamine
and xylazine, and then positioned in a stereotaxic frame.
Deep anesthesia, breathing and body temperature were
maintained throughout the surgical procedures. Mice
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were injected with insulin in a dose of 2 I.U/kg body
weight. The skull was exposed by incising the scalp. Cra-
niotomy was performed with a drill at (−2.5 mm,
−2.2 mm) from the bregma line and midline respectively.
Stainless syringe (Hamilton, Reno, NV) was inserted into
2.1 mm depth, in which the position corresponding to
the right hippocampus. 2.0 μl of insulin solution or arti-
ficial cerebrospinal fluid (aCSF) was injected manually to
the targeted tissue at a rate of 1.0 μl/min. Needle was
left in place for an additional 5 min to prevent liquid
backflow. Mice were sacrificed and decapitated 30 min
after injection. Brains were dissected out and the hippo-
campi were collected for immunoblotting analysis.
Cell culture and RNAi transfection
Human neuroblastoma cell line (SH-SY5Y) was used
in this study. To establish insulin resistance neuro-
blastoma cells (SH-SY5YIR), SH-SY5Y cells were pre-
treated with high concentration insulin (1000 nmol/L)
for 48 h to induce intrinsic insulin resistance. Mam-
malian expressed trimeric Adiponectin (APNTri) was
purified as described before. For cell overexpressing
APP mutant, SH-SY5Y cells was stably transfected
with Swedish mutant of APP (sw-APP) and cultured
in DMEM/F12 with 10%FBS as described before [31].
Double sheath RNAi of scramble RNA, AdipoR1 and
AdipoR2 were performed and the sequence of RNAi
used as described previously [57]. Cells were pre-
treated with either APNTri (10 μg/mL) or Compound
C (Calbiochem, USA) 1 h before culturing with
10 nmol/L insulin. Cells were collected and lysed for
immunoblotting analysis. Culture medium was collected
for ELISA after culturing cells with APN for 48 h.
Aβ quantification
Sandwich enzyme-linked immunosorbent assay (ELISA)
was performed as described previously [58] by mouse
Beta Amyloid 42 and human Beta Amyloid 42 ELISA
kits (Thermo Fisher Scientific, US).
CSF collection and dot blot immunoassay
Mice were deeply anesthetized with Ketamine/Xylazine.
CSF was withdrawn by glass capillary from the cisterna
magna as described previously [59]. For Dot Blot im-
munoassay, 1 μl of CSF was added onto a nitrocellulose
membrane. Full length recombinant mouse Adiponectin
protein was serially diluted and 1 μl of the serial diluted
protein was added on the nitrocellulose membrane for
standard curve. Membrane was dried in air for 1 h at
room temperature and blocked by 5% non-fat milk/
TBST. Membrane was then incubated with rabbit-anti-
adiponectin (1:1000; AIS HKU, HK) at room temperature
for 1 h followed by 30 min HRP conjugated Goat-
anti-rabbit IgG antibody. Signal was developed by
Westernbright Quantum HRP substrate (advansta, USA).
Cell lysis and immunoblotting
For Immunoblotting, mice were sacrificed and decapi-
tated. Brains were dissected on ice. Frontal cortex and
hippocampi were collected and homogenized in lysis
buffer by sonication. Homogenates were centrifuged at
12,000 g for 10 min. Supernatants were aliquoted and
kept at −80 °C. Protein concentration was determined by
Bradford assay (Biorad, USA). 20 μg of the cell homoge-
nates were subjected to 10% SDS polyacrylamide gels
and transferred onto polyvinylidene fluoride (PVDF)
membrane. Immunoblotting was performed as described
previously [60]. Primary antibodies including rabbit-anti-
IRS-1pS616 (Invitrogen, CA), mouse-anti-pGSK3αS21
(Cell Signaling Tech. Inc, USA), rabbit anti-GSK3α (Cell
Signaling Tech. Inc, USA), rabbit anti-pGSK3βS9 (Cell
Signaling Tech. Inc, USA), rabbit anti-GSK3β (Cell Sig-
naling Tech. Inc, USA), rabbit anti-Erk1/2 (Cell Signal-
ing Tech. Inc, USA), rabbit-anti-pErk1/2 (Cell Signaling
Tech. Inc, USA), rabbit-anti-pAktS473 (Cell Signaling
Tech. Inc, USA), rabbit-anti-Akt (Cell Signaling Tech.
Inc, USA), rabbit anti-AMPK (cell signaling Tech. Inc,
USA), rabbit anti-pAMPKT172 (Cell Signaling Tech. Inc,
USA), rabbit anti-IRS-1 (Cell Signaling Tech. Inc, USA),
mouse anti-MHCII (AbDSerotec., UK), rabbit-anti-
pTaupS199pS202 (Invitrogen, USA), and mouse-anti-Tau5
(Invitrogen, USA), mouse-anti-synaptophysin (Invitro-
gen, USA), and HRP-conjugated β-actin (Cell Signaling
Tech. Inc, USA) were incubated at 4 °C overnight
followed by stringent wash with TBS-Tween20. The
PVDF membranes were incubated with HRP-conjugated
secondary antibodies (goat anti-rabbit, 1:5000 or rabbit
anti-mouse, 1:7000; Dako, Glostrup, Denmark).
Tissues processing, immunohistochemistry and
immunofluorescence staining
For immunohistochemistry, mice were anesthetized with
Ketamine/Xylazine. Dissected brains were fixed over-
night in 4% paraformaldehyde at 4 °C. Fixed brains were
dehydrated in gradient ethanol followed by xylene and
embedded in paraffin wax. Sections were rehydrated by
graded ethanol to water. Antigens retrieval was
performed by incubating sections with 10 mM citrate
buffer. Endogenous peroxidase was inactivated by hydro-
gen peroxide solution. Sections were incubated with
primary antibodies, goat anti-GFAP (Santa Cruz, US),
mouse monoclonal anti-Aβ (4G8, Biolegend), and rabbit
anti-Iba-1 (Wako, Japan) at 4 °C overnight. Sections
were incubated with either rabbit anti-mouse or rabbit
anti-goat (1:200; Dako, Glostrup, Denmark). Brown color
staining was developed and counterstained with
hematoxylin. Quantification of staining was performed
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as described previously [58, 61]. For immunofluorescent
staining, sections were incubated with rabbit anti-AdipoR1
(ab70362, Abcam, UK) at 4 °C overnight, followed by
Donkey anti-rabbit IgG Alexa Fluor® 594-conjugated
secondary antibody (Thermofisher, US) for 30 mins. Sec-
tions were mounted by slow fade® anti-fade DAPI reagent
(Lifetech, US).
Thioflavin S staining
Brain sections were deparaffinized by xylene followed by
gradient ethanol treatments (100, 95 70%, 50%) for 3
mins each. Sections were then incubated with 0.5%
Thioflavin S in 50% ethanol for 30 min. Sections were
then washed with 50% ethanol and dehydrated with
gradient ethanol. Sections were mounted by DPX
reagent.
Quantification of neuronal apoptotic cells
To detect neuronal apoptotic cells, sections were treated
with 0.1 M citrate buffer at 90 °C (pH 6.0) for antigen
retrieval. TUNEL assay was used with an in-situ cell
death detection kit (Roche, Mannheim, Germany)
followed by incubating with mouse monoclonal primary
anti-NeuN antibody (MAB377; Millipore, US) at 4 °C
overnight. Sections were then incubated with donkey
anti-mouse IgG Alexa Fluor® 594-conjugated secondary
antibody (Thermofisher, US) for 30 mins. Sections
were mounted by slow fade® anti-fade DAPI reagent
(Lifetech, US).
To quantify the degree of apoptotic cell death in the
cortex and hippocampus, ten coronal sections from
rostro-to-caudal region of the cortex and hippocampus
were examined and TUNEL-positive cells were manually
counted in a defined sampling region. One sampling re-
gion of interest from the hippocampal CA1 and two
sampling regions in the cortex were defined. Only
TUNEL-label cells colocalized with condensed nuclei
staining were counted. The number of TUNEL-positive
cells was the sum of apoptotic cell counts from all
sample fields in the quantified sections of one embedded
block. The number of TUNEL-positive cells reported
was the mean of n number in each group.
Statistics
Dot blot immunoassay, western blot data and immuno-
histochemistry staining were quantified by ImageJ and
presented as group mean ± S.E.M. Statistical analyses
were performed by using unpaired Student t-test or one
way ANOVAs followed by Newman-Keuls multiple
comparison test. Behavioral tests data were analyzed by
one-way ANOVA followed by Bonferroni’s correction
for multiple testing. Behavioral tests results were pre-
sented as mean ± S.E.M with p <0.05 considered as
statistically significant.
Additional files
Additional file 1: AdipoR1 expression in brain and dot-blot immunoassay
of CSF adiponectin. (a) Immunofluorescent analysis of AdipoR1 in cortex
and hippocampus of adult mouse. (b) Standard curve of full length mouse
adiponectin (0-1000 ng/mL). (c) Representative dot-blot image of the serial
diluted APN and CSF from 18-month old WT and APN-KO mice. (d) Dot-blot
immunoassay of APN concentration in the CSF for both WT and APN-KO mice
by 18 months. APN was undetectable in CSF of APN-KO mice. *p < 0.05; WT
(n= 4) vs APN-KO (n= 3). (JPG 57 kb)
Additional file 2: Behavioral Tests. (a) Swim speeds of WT and APN-KO
mice by 9-months and 18 months in Morris-Water-Maze tests displayed
no significant difference (p > 0.05) indicating the escape latency observed
was not due to locomotor defects. (b) Study design of fear-conditioning
contextual and cue tests. (JPG 33 kb)
Additional file 3: Selected frame of the contextual test for wildtype
(left) and APN-KO (right) mice. APN-KO mice froze significantly less than
wildtype mice. (MP4 3153 kb)
Additional file 4: Selected frame of the cue test for wildtype (left) and
APN-KO (right) mice. The clip includes first section of 30-s tone and 30-s
rest afterwards. Tone starts at 0” and ends at 30” in the clip. APN-KO mice
froze significantly less than wildtype mice. (MP4 2612 kb)
Additional file 5: Representative immunoblotting analysis of the levels
of insulin signaling effectors (pErk1/2, pGSK3α21, pGSK3αY279) in (a) 9-mth-old
& (b) 18-mth-old WT and APN-KO mice. Densitometric analysis of the ratio of
pErk1/2/Erk1/2, pGSK3α21/GSK3α and pGSK3αY279∕GSK3α in the hippocampus
and frontal cortex of the APN-KO mice or WT mice by (c) 9-mths-of-age and
(d) 18-mths-of-age. Mean± S.E.M.; *p< 0.05, **p< 0.01, ***p< 0.001, n.s. statistically
not significant; WT (n=3) vs APN-KO (n=3 or 4). (JPG 72 kb)
Additional file 6: (a) Immunoblotting analysis of IRβ in the
hippocampus and frontal cortex of 18-month old wildtype and APN-KO
mice. (b) Densitometric analysis of the ratio of IRβ. Mean ± S.E.M.;
***p < 0.001, n.s. statistically not significant; Scale bar: 100 μm. (JPG 30 kb)
Additional file 7: Cerebral insulin injection to the right hippocampus.
(a) 2 μl of insulin (0.05I.U) or artificial cerebrospinal fluid were injected to
the right hippocampus (coordination: 2.5 mm [D-V]; 2.2 mm [A-P]; 2.1 mm
[Lateral] from Bregma) of 12-mth-old mice. (b) Trypan Blue dye was injected
to the same coordination of the right hippocampus indicated successful
injection. (JPG 35 kb)
Additional file 8: APN enhances insulin sensitivity in neuronal cells with
insulin resistance. SH-SY5Y neuroblastoma cell pretreated with high
concentration insulin (1 μmol/L) for 48 h to induce insulin resistance (SH-SY5YIR).
Western blotting of pAMPK, pAkt and pGSK3βS9 levels of the SH-SY5YIR cells that
treated with 10 nmol/L insulin, 10 μg/mL APNTri & 10 nmol/L insulin
with/without compound C (2 μM) for 24 h. (JPG 46 kb)
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